癌症研究
免疫系统
生物
信号转导
细胞
细胞生物学
MAPK/ERK通路
免疫学
遗传学
作者
Charlotte Rothfuß,Tobias Baumann,Sainitin Donakonda,Bettina Brauchle,Anetta Marcinek,Christian Urban,Julia Mergner,Anna‐Marie Pedde,Anna Hirschberger,Christina Krupka,Anne-Sophie Neumann,Gerulf Hänel,Camilla Merten,Rupert Öllinger,Judith S. Hecker,Tanja Bauer,Christian Schmid,Katharina S. Götze,Jennifer Altomonte,Veit Bücklein
出处
期刊:Blood
[Elsevier BV]
日期:2025-01-21
标识
DOI:10.1182/blood.2024025706
摘要
Loss of anticancer NK cell function in AML patients is associated with fatal disease progression and remains poorly understood. Here, we demonstrate that AML-blasts isolated from patients rapidly inhibit NK cell function and escape NK cell-mediated killing. Transcriptome analysis of NK cells exposed to AML-blasts revealed increased CREM expression and transcriptional activity, indicating enhanced cAMP signalling, confirmed by uniform production of the cAMP-inducing prostanoid PGE2 by all AML-blast isolates from patients. Phosphoproteome analysis disclosed that PGE2 induced a blockade of LCK-ERK signalling that is crucial for NK cell activation, indicating a two-layered escape of AML-blasts with low expression of NK cell-activating ligands and inhibition of NK cell signalling. To evaluate the therapeutic potential to target PGE2 inhibition, we combined Fcg-receptor-mediated activation with the prevention of inhibitory PGE2-signalling. This rescued NK cell function and restored the killing of AML-blasts. Thus, we identify the PGE2-LCK signalling axis as the key barrier for NK cell activation in two-layered immune escape of AML-blasts that can be targeted for immune therapy to reconstitute anti-cancer NK cell immunity in AML patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI